ContraFect Corp. (NASDAQ: CFRX) is a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. The company is finding answers to drug-resistant and newly-emerging pathogens that are responsible for hospital-based infections, the fourth leading cause of death in the U.S., and developing powerful new molecular treatments to kill these deadly microbes, which become resistant through mutation and cause worldwide pandemics, and to revolutionize medicine. For more information, visit the company’s website at www.contrafect.com.